Drug Innovation

Commentary

Democrats $3.5 Trillion Budget Leaves the Health Care Sector as Broken as Ever

One of the most striking aspects of the $3.5 trillion budget resolution proposed last week by Senate Democrats is how little it does to improve America’s ailing healthcare system. The plan funnels massive sums of money into everything from Medicare and Medicaid to Obamacare’s premium tax credits. But it utterly fails to
Commentary

Biden’s Intellectual Property Waiver Puts Political Symbolism Before Saving Lives

President Biden recently backed a World Trade Organization proposal to waive intellectual property protections on COVID-19 vaccines and therapies — a move the Trump administration rejected just a few months ago. The White House’s decision is a catastrophe. The waiver will do nothing to increase access to vaccines. It will, however, undermine the system
Commentary

Trump wrongly attacks life-saving drug companies on coronavirus vaccines and more

President Trump announced Friday that he will proceed with his plans to peg the prices of certain drugs prescribed largely at doctors’ offices under Medicare Part B to the lower prices that other developed nations pay for those drugs. That may sound good at first glance, but in reality, the move will slow
Drug Importation

NEW BRIEF: Counterfeit Drugs Harm Patients, Economy, Innovation

A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm’s way, hinder drug innovation, and lead to job losses. Proposals like drug importation or price controls, if implemented, would exacerbate the problem and
Commentary

Price Controls Are Disastrous For Rents And Will Be For Drugs

President Trump and senior advisor Jared Kushner claim that the most favored nation executive order signed by the President over the weekend is necessary for drug pricing because “the U.S. shouldn’t pay more than other European countries for the same treatments.” This policy will make things worse, not better. If the president
Commentary

President Trump’s Big Government Instincts Threaten Drug Innovation And Availability

President Reagan famously said, “the nine most terrifying words in the English language are: I’m from the Government and I’m here to help”. It is time for President Trump to learn this wisdom. Along with Speaker Pelosi, Senator Sanders, and Representative Ocasio-Cortez, President Trump seems to believe that giving the
Commentary

Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme

The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And,
Blog

What We’re Watching – Good Friday Edition

Tim Anaya – The Crossroads of Innovation and Affordability In the latest “Escape the Drug Pricing Maze” video, On the first step toward escaping the Drug Pricing Maze, Professor Salvare takes Pete Paystoomuch down the path of drug innovation, showing him why drug prices are initially more expensive – to
Drug Innovation

Sally C. Pipes Discusses Changing Drug Regulations on the Lars Larson Show

Sally C. Pipes joins the Lars Larson Show on KXL to discuss how new regulations will change drug prices in Canada and discourage drug innovation.
Commentary

Don’t Slash Medicare In Last – Minute Budget Agreement

The weather isn’t the only thing heating up in Washington. White House officials are feverishly negotiating with congressional leaders to raise the debt ceiling and reach a two-year budget deal that averts more than $126 billion in automatic spending cuts. Democrats want the deal to dramatically raise domestic spending levels. Republicans
Commentary

Democrats $3.5 Trillion Budget Leaves the Health Care Sector as Broken as Ever

One of the most striking aspects of the $3.5 trillion budget resolution proposed last week by Senate Democrats is how little it does to improve America’s ailing healthcare system. The plan funnels massive sums of money into everything from Medicare and Medicaid to Obamacare’s premium tax credits. But it utterly fails to
Commentary

Biden’s Intellectual Property Waiver Puts Political Symbolism Before Saving Lives

President Biden recently backed a World Trade Organization proposal to waive intellectual property protections on COVID-19 vaccines and therapies — a move the Trump administration rejected just a few months ago. The White House’s decision is a catastrophe. The waiver will do nothing to increase access to vaccines. It will, however, undermine the system
Commentary

Trump wrongly attacks life-saving drug companies on coronavirus vaccines and more

President Trump announced Friday that he will proceed with his plans to peg the prices of certain drugs prescribed largely at doctors’ offices under Medicare Part B to the lower prices that other developed nations pay for those drugs. That may sound good at first glance, but in reality, the move will slow
Drug Importation

NEW BRIEF: Counterfeit Drugs Harm Patients, Economy, Innovation

A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm’s way, hinder drug innovation, and lead to job losses. Proposals like drug importation or price controls, if implemented, would exacerbate the problem and
Commentary

Price Controls Are Disastrous For Rents And Will Be For Drugs

President Trump and senior advisor Jared Kushner claim that the most favored nation executive order signed by the President over the weekend is necessary for drug pricing because “the U.S. shouldn’t pay more than other European countries for the same treatments.” This policy will make things worse, not better. If the president
Commentary

President Trump’s Big Government Instincts Threaten Drug Innovation And Availability

President Reagan famously said, “the nine most terrifying words in the English language are: I’m from the Government and I’m here to help”. It is time for President Trump to learn this wisdom. Along with Speaker Pelosi, Senator Sanders, and Representative Ocasio-Cortez, President Trump seems to believe that giving the
Commentary

Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme

The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And,
Blog

What We’re Watching – Good Friday Edition

Tim Anaya – The Crossroads of Innovation and Affordability In the latest “Escape the Drug Pricing Maze” video, On the first step toward escaping the Drug Pricing Maze, Professor Salvare takes Pete Paystoomuch down the path of drug innovation, showing him why drug prices are initially more expensive – to
Drug Innovation

Sally C. Pipes Discusses Changing Drug Regulations on the Lars Larson Show

Sally C. Pipes joins the Lars Larson Show on KXL to discuss how new regulations will change drug prices in Canada and discourage drug innovation.
Commentary

Don’t Slash Medicare In Last – Minute Budget Agreement

The weather isn’t the only thing heating up in Washington. White House officials are feverishly negotiating with congressional leaders to raise the debt ceiling and reach a two-year budget deal that averts more than $126 billion in automatic spending cuts. Democrats want the deal to dramatically raise domestic spending levels. Republicans
Scroll to Top